The quantitative association mechanism between inflammatory response and oxidative stress in cardiorenal syndrome remains unclear. This study investigates the dynamic changes of neutrophil gelatinase-associated lipocalin (NGAL) and interleukin-18 (IL-18) in early renal injury and their correlation with myocardial remodeling. It included 45 patients with cardiorenal syndrome meeting the Framingham criteria. Serum NGAL and IL-18 concentrations are quantitatively detected at baseline, week 4, and week 8 using enzyme-linked immunosorbent assay (ELISA). Concurrently, cardiac magnetic resonance imaging (CMR) is used to quantify the left ventricular mass index (LVMI) and global longitudinal strain, and high-performance liquid chromatography-mass spectrometry (HPLC-MS) is employed to determine urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels to assess systemic oxidative stress status. NGAL and IL-18 showed a continuous increase over 8 weeks, and urinary 8-OHdG levels increased by 51.4% in the significant remodeling group. The dynamic changes of NGAL, IL-18, and 8-OHdG sensitively reflect the myocardial remodeling process in CRS patients, providing potential targets for early intervention.

Zeng Xiaofang, Huang Hua, Zeng Tao. Advances in the Pathophysiological Mechanisms and Treatment Research of Cardiorenal Syndrome. International Journal of Public Health and Preventive Medicine (2022), Vol. 3, Issue 1: 34-41. 

[1] McCallum W, Sarnak M J. Cardiorenal syndrome in the hospital[J]. Clinical Journal of the American Society of Nephrology, 2023, 18(7): 933-945.

[2] Zoccali C, Mallamaci F, Halimi J M, et al. From cardiorenal syndrome to chronic cardiovascular and kidney disorder: a conceptual transition[J]. Clinical Journal of the American Society of Nephrology, 2024, 19(6): 813-820.

[3] Junho C V C, Trentin-Sonoda M, Panico K, et al. Cardiorenal syndrome: long road between kidney and heart[J]. Heart failure reviews, 2022, 27(6): 2137-2153.

[4] Prastaro M, Nardi E, Paolillo S, et al. Cardiorenal syndrome: Pathophysiology as a key to the therapeutic approach in an under‐diagnosed disease[J]. Journal of Clinical Ultrasound, 2022, 50(8): 1110-1124.

[5] Patel K P, Katsurada K, Zheng H. Cardiorenal syndrome: the role of neural connections between the heart and the kidneys[J]. Circulation research, 2022, 130(10): 1601-1617.

[6] Méndez A B, Azancot M A, Olivella A, et al. New aspects in cardiorenal syndrome and HFpEF[J]. Clinical kidney journal, 2022, 15(10): 1807-1815.

[7] León-Román J, Azancot M A, Marouco C, et al. A New Era in the Management of Cardiorenal Syndrome: The Importance of Cardiorenal Units[J]. Cardiorenal Medicine, 2025, 15(1): 174-183.

[8] McCullough P A. Anemia of cardiorenal syndrome[J]. Kidney International Supplements, 2021, 11(1): 35-45.

[9] Chávez-Iñiguez J S, Sánchez-Villaseca S J, García-Macías L A. Cardiorenal syndrome: classification, pathophysiology, diagnosis and management. Literature review[J]. Arch Cardiol Mex, 2022, 92(2): 253-263.

[10] McCallum W, Testani J M. Updates in cardiorenal syndrome[J]. Medical Clinics of North America, 2023, 107(4): 763-780.

[11] Ricci Z, Romagnoli S, Ronco C. Cardiorenal syndrome[J]. Critical care clinics, 2021, 37(2): 335-347.

[12] Hatamizadeh P. From cardiorenal syndrome to nephrocardiology: the journey of exploring the interconnection between nephrology and cardiovascular medicine[J]. Trends in cardiovascular medicine, 2024, 34(8): 541-546.

[13] Islas-Rodríguez J P, Miranda-Aquino T, Romero-González G, et al. Effect on kidney function recovery guiding decongestion with VExUS in patients with cardiorenal syndrome 1: a randomized control trial[J]. Cardiorenal Medicine, 2024, 14(1): 1-11.

[14] Pradhan S K, Adnani H, Safadi R, et al. Cardiorenal syndrome in the pediatric population: A systematic review[J]. Annals of Pediatric Cardiology, 2022, 15(5 & 6): 493-510.

[15] Hatamizadeh P. Cardiorenal syndrome: an important subject in nephrocardiology[J]. Cardiology Clinics, 2021, 39(3): 455-469.